Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 2 of the last 2 fiscal years.
-
Two loss years in a row NBB
Negative result in 2021 and 2022.
-
Annual account missing NBB
Fiscal year 2023 was expected before 31 July 2024 and has not been filed.
-
Busy address KBO
12 other companies have their registered office at the same address; threshold 10.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2022
THERACELL ADVANCED BIOTECHNOLOGY (Belgium) from Marche-en-Famenne, company number BE0731712273, closed financial year 2022 with a result of € -128,310 after tax. For that financial year THERACELL ADVANCED BIOTECHNOLOGY (Belgium) recorded a gross margin of € -37,200 and equity of € -179,076. Compared with financial year 2021, the result moved from € -66,861 to € -128,310. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 14, 2023.
€ -179,076
▼ € 128,310 vs 2021
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -128,310
▼ 92 % more loss than in 2021
Profit after tax over the fiscal year.
€ 206,628
▼ 55% vs 2021
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -197,676.
People and assets in 2022
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 89,885
▲ 61% vs 2021
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2022
€ 489,901
Loans from banks and other lenders, long and short.
€ 11,378
▲ 18% vs 2021
Supplier invoices still open on the last day of the fiscal year.
€ 5,630
▼ 31% vs 2021
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | Change 2021 → 2022 | |
|---|---|---|---|
| Gross margin | € -9,979 | € -37,200 | ▼ € 27,221 |
| Profit after taxes | € -66,861 | € -128,310 | ▼ € 61,449 |
| Equity | € -50,765 | € -179,076 | ▼ € 128,310 |
| Total debts | € 507,625 | € 506,909 | |
| Cash | € 455,794 | € 206,628 | ▼ 55% |
| Retained profit | € -69,365 | € -197,676 | ▼ € 128,310 |
| Bank debt | € 489,901 | € 489,901 | |
| Balance sheet total | € 456,860 | € 327,833 | ▼ 28% |
Key figures of THERACELL ADVANCED BIOTECHNOLOGY (Belgium), fiscal years 2021 to 2022, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2023 has not been filed yet; it was expected before 31 July 2024.
What happened to THERACELL ADVANCED BIOTECHNOLOGY (Belgium)?
What happened at THERACELL ADVANCED BIOTECHNOLOGY (Belgium) in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2022: loss of € 128,310. Source: NBB ↗
- Start of the company according to the CBE. KBO
In short
From € 66,861 loss in 2021 to € 128,310 loss in 2022.
A new publication or filing at THERACELL ADVANCED BIOTECHNOLOGY (Belgium)? We notify you, reason included.
Follow THERACELL ADVANCED BIOTECHNOLOGY (Belgium)Databakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind THERACELL ADVANCED BIOTECHNOLOGY (Belgium) is Fotios Sakellaridis.
Directors
According to the 2022 annual accounts
Fotios Sakellaridis
Director
Establishments
Establishment units
Physical locations of this company
Aye, Rue de la Science 8
6900 Marche-en-Famenne
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 12 companies are registered at this address.
All companies at this address →Association pour le développement des Productions Agroalimentaires de qualité
CER-Groupe
€ 22.4 million revenue · 2025
Association pour l'Usage et la Défense de l'Appellation Jambon d'Ardenne
Orgenesis (Belgium)
€ 1.4 million gross margin · 2021
RevaTis
€ 136,602 gross margin · 2025
+7 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
AMAZON-02 - Amazon.com, Inc., US
Website info
Features
Security
Details
- Company number
- 0731.712.273
- VAT number
- BE 0731.712.273
- Registered office
- Aye, Rue de la Science 8, 6900 Marche-en-Famenne
- Names & denominations
- THERACELL ADVANCED BIOTECHNOLOGY (Belgium)
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 30 July 2019
- Peppol
- Not registered
- Contact
- theracell.eu
- Activities · NACE
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Speur- en ontwikkelingswerk op biotechnologisch gebied